亚虹医药

?? Exciting news! The Phase II study of APL-1202 + tislelizumab for muscle-invasive bladder cancer shows a 41% pCR rate, a boost from 20% with tislelizumab alone. This combo is particularly effective for PD-L1 low-expression tumors. Asieris is committed to advancing treatments for genitourinary diseases! ?? Read more https://ow.ly/kSwR50V0l2b #ClinicalTrials #BladderCancer #Innovation #GU25 American Society of Clinical Oncology (ASCO)

?? Happy Lunar New Year 2025! ?? As we welcome this joyous occasion, Asieris Pharmaceuticals wishes you and your loved ones a year filled with health, prosperity, and success. Let’s embrace the opportunities and new beginnings this year brings as we continue our journey of innovation and excellence together. #HappyLunarNewYear #NewBeginnings #AsierisPharma

We are thrilled to announce that the National Medical Products Administration (NMPA) has approved our Investigational New Drug (IND) application for a novel USP1 inhibitor. This breakthrough therapy targets advanced solid tumors, showcasing our commitment to advancing oncology treatments. This milestone highlights our dedication to developing innovative therapies that address unmet medical needs in cancer treatment. Learn more about this significant step in our journey: https://ow.ly/UvxT50UIbY1 #OncologyInnovation #CancerResearch #INDApproval #USP1Inhibitor #HealthcareAdvances

We are thrilled to announce that Helen Xu has been appointed as Chief Commercial Officer at Asieris Pharmaceuticals! With her impressive expertise in commercialization and strategic growth, Helen is set to lead our efforts in advancing our innovative therapeutics to benefit patients worldwide. Join us in welcoming Helen to the team. Read more about her role and vision here: https://ow.ly/mbtu50UFHvt #Leadership #Innovation #LifeSciences

We are thrilled to share that Asieris Pharmaceuticals has entered into an Investigational Product Supply Agreement with the Centers for Disease Control and Prevention (CDC) to provide APL-1202 for the treatment of free-living amoeba infections. This agreement allows APL-1202 to be made available under the Expanded Access Investigational New Drug Program, addressing a critical need for rare but severe diseases. Read the full announcement here: https://ow.ly/Qcfb50UAPyU #InnovationInHealthcare #Pharmaceuticals #APL1202 #RareDiseases #HealthcareSolutions

Reflecting on a year of advancements in healthcare, Asieris Pharmaceuticals wishes you a holiday season filled with professional success and personal well-being. We look forward to continuing our work towards innovative solutions in the new year. #Biotech #Pharmaceuticals #Healthcare #Innovation

?? Exciting Leadership Announcement! ?? Asieris Pharmaceuticals is thrilled to welcome Joanna Zhang as our new Chief Medical Officer (CMO)! With her outstanding expertise and leadership in clinical development and global healthcare, Joanna will play a pivotal role in advancing our mission to innovate and improve patient outcomes worldwide. Learn more about this exciting addition to our team: https://ow.ly/VWSI50Ubg1V #Leadership #Innovation #Healthcare #AsierisPharma

We're thrilled to announce that Asieris Pharmaceuticals has shared groundbreaking results at the 2024 International Papillomavirus Conference (IPVC) ! Our latest analysis focuses on HPV clearance rates for different types and follow-up times using non-surgical treatments for cervical HSIL. This advancement brings us closer to more effective and accessible solutions in HPV-related health. Our commitment to innovation and women’s health drives us to uncover new pathways for prevention and treatment. Explore the full study and its potential impact: https://ow.ly/igpv50U5NC3 #IPVC2024

We're delighted to announce that Asieris Hong Kong and SPH Keyuan Trade have signed a strategic cooperation agreement at the China International Import Expo (CIIE)! This partnership represents a significant milestone as we strengthen our joint efforts in the healthcare sector, aiming to deliver innovative solutions and broaden access to quality care. Collaborations like this are essential for driving progress and fostering impactful change in global health. Learn more about this important step forward: https://ow.ly/ybLF50U2MnV

We’re excited to announce that Asieris Pharmaceuticals has signed a strategic cooperation agreement with the China Women’s Development Foundation! This collaboration marks the launch of the Fertility-Friendly Cervical Health Initiative, aimed at supporting women's reproductive health and raising awareness about cervical health. By combining expertise and resources, we are paving the way for innovative healthcare solutions and greater support for women’s well-being. Read more about this partnership and its impact: https://ow.ly/Vlew50U2MkG